FGFR3IgH MM Test sale cost 1050 AED
BCR-ABL CML AML ALL Test sale cost 1050 AED BCR-ABL CML AML ALL Test Cost Original price was: 1.400,00 د.إ.Current price is: 1.050,00 د.إ.
TELAML ALL Test sale cost 1050 AED TELAML ALL Test Cost Original price was: 1.400,00 د.إ.Current price is: 1.050,00 د.إ.
Sale!

FGFR3IgH MM Test Cost

Original price was: 1.400,00 د.إ.Current price is: 1.050,00 د.إ.

-25%

The FGFR3IgH MM Test is a specialized diagnostic assay conducted at DNA Labs UAE, designed to identify specific genetic abnormalities associated with multiple myeloma, a type of blood cancer. This test focuses on detecting translocations and mutations in the FGFR3 gene and its interaction with the IgH gene, which are critical markers for diagnosing and understanding the prognosis of the disease. By analyzing the genetic material from a patient’s blood or bone marrow sample, the FGFR3IgH MM Test can provide valuable information that aids in tailoring personalized treatment strategies for individuals with multiple myeloma. The cost of the test is 1050 AED, reflecting the sophisticated technology and expertise required to perform this advanced genetic analysis. DNA Labs UAE, where this test is conducted, is equipped with state-of-the-art facilities and employs highly skilled professionals to ensure accurate and reliable results.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

FGFR3IgH MM Test

Test Name: FGFR3IgH MM Test

Components: Sodium Heparin Vacutainer (2ml)

Price: 1050.0 AED

Sample Condition: Bone Marrow / Peripheral blood

Report Delivery: 3-4 days

Method: FISH

Test Type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: FGFR3/IgH (MM) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details:

FGFR3/IgH (MM) refers to a chromosomal translocation that is commonly found in a subtype of multiple myeloma (MM) called t(4;14)(p16;q32). This translocation involves the fusion of the FGFR3 (fibroblast growth factor receptor 3) gene on chromosome 4 with the IgH (immunoglobulin heavy chain) gene on chromosome 14. The FGFR3/IgH fusion gene results in the overexpression of FGFR3, a receptor tyrosine kinase involved in cell growth and differentiation. This dysregulated expression of FGFR3 contributes to the development and progression of multiple myeloma.

Patients with FGFR3/IgH translocation in their multiple myeloma have been found to have distinct clinical and biological characteristics. They tend to have a more aggressive disease course, higher tumor burden, and poorer prognosis compared to other subtypes of multiple myeloma. Understanding the presence of FGFR3/IgH translocation in multiple myeloma patients can be important for risk stratification and treatment planning. Targeted therapies that specifically inhibit FGFR3 signaling may be considered as a treatment option for these patients.

Test Name FGFR3IgH MM Test
Components Sodium Heparin Vacutainer (2ml)
Price 1050.0 AED
Sample Condition Bone Marrow \/ Peripheral blood
Report Delivery 3-4 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information FGFR3/IgH (MM) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

FGFR3/IgH (MM) refers to a chromosomal translocation that is commonly found in a subtype of multiple myeloma (MM) called t(4;14)(p16;q32). This translocation involves the fusion of the FGFR3 (fibroblast growth factor receptor 3) gene on chromosome 4 with the IgH (immunoglobulin heavy chain) gene on chromosome 14.

The FGFR3/IgH fusion gene results in the overexpression of FGFR3, a receptor tyrosine kinase involved in cell growth and differentiation. This dysregulated expression of FGFR3 contributes to the development and progression of multiple myeloma.

Patients with FGFR3/IgH translocation in their multiple myeloma have been found to have distinct clinical and biological characteristics. They tend to have a more aggressive disease course, higher tumor burden, and poorer prognosis compared to other subtypes of multiple myeloma.

Understanding the presence of FGFR3/IgH translocation in multiple myeloma patients can be important for risk stratification and treatment planning. Targeted therapies that specifically inhibit FGFR3 signaling may be considered as a treatment option for these patients.

SKU: TEST-5548 Category:

Related products